Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers

Tsuyoshi Shiga, Masayuki Hashiguchi, Koichi Nakamura, Mikiko Shimizu, Kaoru Shimizu, Atsushi Suzuki, Mayumi Mochizuki, Nobuhisa Hagiwara

Research output: Contribution to journalArticle

Abstract

Pilsicainide, a class Ic antiarrhythmic agent, is a cationic compound. It has been hypothesized that a P-glycoprotein(P-gp)-induced transport mechanism may mediate the intestinal absorption and the renal excretion of pilsicainide. We evaluated whether rifampicin, a known inducer of P-gp, affects the pharmacokinetics of pilsicainide after oral dosing in healthy subjects. A pharmacokinetic study was conducted on 8 healthy male subjects (aged 30 ±8 years: body weight 65.7 ±6.5 kg) and demonstrated that rifampicin (450 mg given orally once daily for 4 days) did not significantly affect the maximum plasma concentration (pilsicainide alone: 0.39 ± 0.15 versus pilsicainide + rifampicin: 0.36±0.06μg/mL), the time to maximum plasma concentration(1.38± 0.83 versus 1.06±0.18h), the area under the plasma concentration-time curve(2.81 ±0.91 versus 2.58±0.62 μg·h/mL), the renal clearance (198.46±85.93 versus 194.34±69.91 mL/min) or the net renal clearance by tubular secretion(128.75±73.56 versus 119.93 ±79.84 mL/min) of pilsicainide after a single oral dose(50 mg). In conclusion, our results indicated that rifampicin did not affect the pharmacokinetics of pilsicainide after oral dosing in humans.

Original languageEnglish
Pages (from-to)301-305
Number of pages5
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume44
Issue number4
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Rifampin
Healthy Volunteers
Pharmacokinetics
P-Glycoprotein
Kidney
Intestinal Absorption
pilsicainide
Body Weight

Keywords

  • Interaction
  • Pharmacokinetics
  • Pilsicainide
  • Rifampicin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers. / Shiga, Tsuyoshi; Hashiguchi, Masayuki; Nakamura, Koichi; Shimizu, Mikiko; Shimizu, Kaoru; Suzuki, Atsushi; Mochizuki, Mayumi; Hagiwara, Nobuhisa.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 44, No. 4, 07.2013, p. 301-305.

Research output: Contribution to journalArticle

Shiga, Tsuyoshi ; Hashiguchi, Masayuki ; Nakamura, Koichi ; Shimizu, Mikiko ; Shimizu, Kaoru ; Suzuki, Atsushi ; Mochizuki, Mayumi ; Hagiwara, Nobuhisa. / Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers. In: Japanese Journal of Clinical Pharmacology and Therapeutics. 2013 ; Vol. 44, No. 4. pp. 301-305.
@article{1a70bcc283dc49b193a8310a2f11c9f0,
title = "Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers",
abstract = "Pilsicainide, a class Ic antiarrhythmic agent, is a cationic compound. It has been hypothesized that a P-glycoprotein(P-gp)-induced transport mechanism may mediate the intestinal absorption and the renal excretion of pilsicainide. We evaluated whether rifampicin, a known inducer of P-gp, affects the pharmacokinetics of pilsicainide after oral dosing in healthy subjects. A pharmacokinetic study was conducted on 8 healthy male subjects (aged 30 ±8 years: body weight 65.7 ±6.5 kg) and demonstrated that rifampicin (450 mg given orally once daily for 4 days) did not significantly affect the maximum plasma concentration (pilsicainide alone: 0.39 ± 0.15 versus pilsicainide + rifampicin: 0.36±0.06μg/mL), the time to maximum plasma concentration(1.38± 0.83 versus 1.06±0.18h), the area under the plasma concentration-time curve(2.81 ±0.91 versus 2.58±0.62 μg·h/mL), the renal clearance (198.46±85.93 versus 194.34±69.91 mL/min) or the net renal clearance by tubular secretion(128.75±73.56 versus 119.93 ±79.84 mL/min) of pilsicainide after a single oral dose(50 mg). In conclusion, our results indicated that rifampicin did not affect the pharmacokinetics of pilsicainide after oral dosing in humans.",
keywords = "Interaction, Pharmacokinetics, Pilsicainide, Rifampicin",
author = "Tsuyoshi Shiga and Masayuki Hashiguchi and Koichi Nakamura and Mikiko Shimizu and Kaoru Shimizu and Atsushi Suzuki and Mayumi Mochizuki and Nobuhisa Hagiwara",
year = "2013",
month = "7",
doi = "10.3999/jscpt.44.301",
language = "English",
volume = "44",
pages = "301--305",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers

AU - Shiga, Tsuyoshi

AU - Hashiguchi, Masayuki

AU - Nakamura, Koichi

AU - Shimizu, Mikiko

AU - Shimizu, Kaoru

AU - Suzuki, Atsushi

AU - Mochizuki, Mayumi

AU - Hagiwara, Nobuhisa

PY - 2013/7

Y1 - 2013/7

N2 - Pilsicainide, a class Ic antiarrhythmic agent, is a cationic compound. It has been hypothesized that a P-glycoprotein(P-gp)-induced transport mechanism may mediate the intestinal absorption and the renal excretion of pilsicainide. We evaluated whether rifampicin, a known inducer of P-gp, affects the pharmacokinetics of pilsicainide after oral dosing in healthy subjects. A pharmacokinetic study was conducted on 8 healthy male subjects (aged 30 ±8 years: body weight 65.7 ±6.5 kg) and demonstrated that rifampicin (450 mg given orally once daily for 4 days) did not significantly affect the maximum plasma concentration (pilsicainide alone: 0.39 ± 0.15 versus pilsicainide + rifampicin: 0.36±0.06μg/mL), the time to maximum plasma concentration(1.38± 0.83 versus 1.06±0.18h), the area under the plasma concentration-time curve(2.81 ±0.91 versus 2.58±0.62 μg·h/mL), the renal clearance (198.46±85.93 versus 194.34±69.91 mL/min) or the net renal clearance by tubular secretion(128.75±73.56 versus 119.93 ±79.84 mL/min) of pilsicainide after a single oral dose(50 mg). In conclusion, our results indicated that rifampicin did not affect the pharmacokinetics of pilsicainide after oral dosing in humans.

AB - Pilsicainide, a class Ic antiarrhythmic agent, is a cationic compound. It has been hypothesized that a P-glycoprotein(P-gp)-induced transport mechanism may mediate the intestinal absorption and the renal excretion of pilsicainide. We evaluated whether rifampicin, a known inducer of P-gp, affects the pharmacokinetics of pilsicainide after oral dosing in healthy subjects. A pharmacokinetic study was conducted on 8 healthy male subjects (aged 30 ±8 years: body weight 65.7 ±6.5 kg) and demonstrated that rifampicin (450 mg given orally once daily for 4 days) did not significantly affect the maximum plasma concentration (pilsicainide alone: 0.39 ± 0.15 versus pilsicainide + rifampicin: 0.36±0.06μg/mL), the time to maximum plasma concentration(1.38± 0.83 versus 1.06±0.18h), the area under the plasma concentration-time curve(2.81 ±0.91 versus 2.58±0.62 μg·h/mL), the renal clearance (198.46±85.93 versus 194.34±69.91 mL/min) or the net renal clearance by tubular secretion(128.75±73.56 versus 119.93 ±79.84 mL/min) of pilsicainide after a single oral dose(50 mg). In conclusion, our results indicated that rifampicin did not affect the pharmacokinetics of pilsicainide after oral dosing in humans.

KW - Interaction

KW - Pharmacokinetics

KW - Pilsicainide

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=84882742802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882742802&partnerID=8YFLogxK

U2 - 10.3999/jscpt.44.301

DO - 10.3999/jscpt.44.301

M3 - Article

AN - SCOPUS:84882742802

VL - 44

SP - 301

EP - 305

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -